Sargent Investment Group, LLC Relmada Therapeutics, Inc. Transaction History
Sargent Investment Group, LLC
- $616 Million
- Q4 2024
A detailed history of Sargent Investment Group, LLC transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Sargent Investment Group, LLC holds 11,670 shares of RLMD stock, worth $3,267. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,670
Previous 21,460
45.62%
Holding current value
$3,267
Previous $69,000
91.3%
% of portfolio
0.0%
Previous 0.01%
Shares
6 transactions
Others Institutions Holding RLMD
# of Institutions
54Shares Held
8.29MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$364,6020.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$351,8770.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$343,8190.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$160,5270.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$138,6400.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $8.01M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...